<DOC>
	<DOCNO>NCT01209091</DOCNO>
	<brief_summary>Introduction : Many reimbursement authority use economic evaluation help guide decision regard adoption new treatment reimbursement system . Survival quality life often main measure benefit use economic evaluation - express quality adjust life year ( QALY ) . In addition though , decision maker also consider impact treatment patient 's ability continue work ( express term productivity ) . The aim present study estimate quality life weight ( utility ) productivity loss woman metastatic breast cancer ( Human Epidermal Growth Factor Receptor 2 positive HER 2+ ) . Methods : Separate survey use assess utility productivity HER2+ metastatic breast cancer ( MBC ) . To capture utility health state description vignette describe progressive disease , stable disease , seven grade 3/4 adverse event ( diarrhoea , fatigue , anaemia , leukopenia , anorexia , decrease leave ventricular ejection fraction ( LVEF ) , skin rash ) develop . The vignette develop base literature review depth interview woman MBC Netherlands Sweden . Clinical expert country review health state content validity . The health state translate use forward back translation . Members general public rate state ( 100 men woman NL ; 100 woman age 50+ Sweden ) use visual analogue scale Time Trade Off method determine utility value . In separate survey woman currently treat recently complete treatment MBC survey regard impact disease ability work use validated work productivity measure ( Work Productivity Activity Impairment ) woman Netherlands Sweden .</brief_summary>
	<brief_title>Utility Work Productivity Data Economic Evaluation Breast Cancer Therapies Netherlands Sweden</brief_title>
	<detailed_description />
	<criteria>Age &gt; 18</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>